Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

UPDATE 1-Philippines lifts suspension on AstraZeneca vaccine for under 60s

Published 04/19/2021, 03:04 PM
Updated 04/19/2021, 03:10 PM
© Reuters.

* 'Benefit outweighs the risk' - official
* Only AstraZeneca (NASDAQ:AZN), Sinovac vaccines is use in Philippines
* Philippines battling surge in cases

(Adds details, background)
MANILA, April 19 (Reuters) - The Philippines will resume
administering AstraZeneca's AZN.L COVID-19 vaccine to people
below 60 years of age, health officials said on Monday, ending a
temporary suspension over reports of rare blood clots in younger
recipients overseas.
"The benefit outweighs the risk. Only a small percentage of
the population had these adverse effects for AstraZeneca,"
Health Undersecretary Maria Rosario Vergeire told a regular news
conference, referring to countries where blood clots were
reported.
Health authorities will release guidelines to include
different precautions on the use of the AstraZeneca shots,
Vergeire added.
The European Medicines Agency had earlier recommended to
include blood clots as a rare side effect of the AstraZeneca
vaccine.
The Southeast Asian nation has yet to record blood clots as
side effect. It suspended the use of AstraZeneca's vaccine for
under 60s on April 8. The Philippines, a country of 108 million people, is
battling one of the worst outbreaks in Asia but has administered
less than 1.5 million shots of COVID-19 vaccines, 86% of which
were first doses.
It has recorded 936,133 COVID-19 cases and 15,960 deaths due
to the virus.
The Philippines has received 525,600 doses of the
AstraZeneca vaccine through the COVAX international
vaccine-share facility. More than 900,000 more were to be
shipped in May or June, according to health ministry data.
Vaccines from China's Sinovac Biotech SVA.O accounts for
83% of doses so far delivered to the Philippines.


Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.